Miikana Therapeutics Inc.
This article was originally published in Start Up
Executive Summary
Miikana Therapeutics Inc. is focused on in-licensing late-stage oncology compounds that fit well with the staff's expertise in cancer pathways effecting apoptosis and mitotic catastrophe. Longer term, it will discover and develop drugs internally against novel but validated targets such as kinases, and histone deacetylases.